---
workflow_id: ISSUE-NUC-20260214-0001
type: synthesis
timestamp: "2026-02-14T15:30:00+09:00"
scope: 01_Nucleus
owner: "agent-hub"
claim_ref: "01_Nucleus/Record_Archive/pending/ISSUE-NUC-20260214-0001-CRITIQUE.md"
counterclaim_ref: "01_Nucleus/Record_Archive/pending/ISSUE-NUC-20260214-0001-CRITIQUE-CLAUDE.md"

# Synthesis: Issue 20260214-0001

## Convergence Points

1) Both critiques agree that the issue is high severity and that provider/model-family 분리 규칙은 필수이다.
2) Both critiques demand measurable governance controls; we rewrote `success_criteria` to KPI 형식 in `PROBLEM_STATEMENT.md`.
3) Both critiques demand stronger evidence/protocol in planning packet; we added `open_agent_council`, `multi_agent_consensus`, `Risk/Impact`, and explicit `evidence_links` in `DELIBERATION_PACKET.md`.

## Open Claimed Items Resolved

- W-PS-1 / W-PS-3 / W-PS-5: solved by adding KPI, risk mitigation, and `issue_signature` in `PROBLEM_STATEMENT.md`.
- W-DP-1 / W-DP-2 / W-DP-4 / W-DP-5 / W-DP-6 / W-DP-7 / W-DP-8: solved by extending `DELIBERATION_PACKET.md` sections and targets.
- W-WM-1 / W-WM-3 / W-WM-4 / W-WM-5: solved by normalizing `model_family` naming, adding timestamps/rationales, and changing cross/dissolution states to execution-invariant values.

## Items Requiring Stage-4 Review (immu)

- W-WM-2 (critic rationale completeness) remains for Immune review to confirm each reviewer's independent checks.

## Synthesis Verdict

- Status: `synthesis-complete` for Stage-3 completion.
- Stage-4 Immune Critique should proceed with `no-critical-objection` if independent runtime checks pass.
- `DELIBERATION_PACKET.md` should move to `status: submitted` and maintain `request`-phase lock until Immune verdict.
